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Abstract
Background: Primary testing for high-risk HPV (hrHPV) is increasingly implemented in cervical cancer screening
programs. Many hrHPV-positive women, however, harbor clinically irrelevant infections, demanding additional
disease markers to prevent over-referral and over-treatment. Most promising biomarkers reflect molecular events
relevant to the disease process that can be measured objectively in small amounts of clinical material, such as
miRNAs. We previously identified eight miRNAs with altered expression in cervical precancer and cancer due to
either methylation-mediated silencing or chromosomal alterations. In this study, we evaluated the clinical value
of these eight miRNAs on cervical scrapes to triage hrHPV-positive women in cervical screening.
Results: Expression levels of the eight candidate miRNAs in cervical tissue samples (n = 58) and hrHPV-positive
cervical scrapes from a screening population (n = 187) and cancer patients (n = 38) were verified by quantitative
RT-PCR. In tissue samples, all miRNAs were significantly differentially expressed (p < 0.05) between normal, high-
grade precancerous lesions (CIN3), and/or cancer. Expression patterns detected in cervical tissue samples were
reflected in cervical scrapes, with five miRNAs showing significantly differential expression between controls and
women with CIN3 and cancer. Using logistic regression analysis, a miRNA classifier was built for optimal detection
of CIN3 in hrHPV-positive cervical scrapes from the screening population and its performance was evaluated using
leave-one-out cross-validation. This miRNA classifier consisted of miR-15b-5p and miR-375 and detected a major
subset of CIN3 as well as all carcinomas at a specificity of 70%. The CIN3 detection rate was further improved by
combining the two miRNAs with HPV16/18 genotyping. Interestingly, both miRNAs affected the viability of
cervical cancer cells in vitro.
Conclusions: This study shows that miRNA expression analysis in cervical scrapes is feasible and enables the early
detection of cervical cancer, thus underlining the potential of miRNA expression analysis for triage of hrHPV-positive
women in cervical cancer screening.
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Background
Cervical cancer screening by cytological examination of
cervical scrapes has largely reduced the incidence and
mortality rates of cervical cancer in developed countries
due to early detection of well-recognizable and treatable
precursor lesions (cervical intraepithelial neoplasia
(CIN), graded 1–3) [1]. Persistent infection with
high-risk types of the human papillomavirus (hrHPV) is
a necessary cause of cervical cancer [2–4]. Testing for
hrHPV DNA has been demonstrated to have a higher
sensitivity for the detection of cervical high-grade
CIN and cancer than the cytology-based Pap smear
[5, 6]. Consequently, hrHPV testing has recently been
implemented as primary screening method in The
Netherlands and various other countries. As hrHPV
testing also detects women with clinically irrelevant
transient infections, additional triage markers are
required to identify women with high-grade CIN le-
sions who are in need of treatment given their risk of
developing cancer. Cytology is the currently recom-
mended triage strategy for hrHPV-positive women.
An ideal triage test, however, should be objective
(non-morphological), available in a high-throughput
format and feasible in low-resource countries. For this
purpose, HPV16/18 genotyping has previously been
investigated as triage test in cervical cancer screening
[7–9]. Additional molecular markers reflecting the
underlying carcinogenic process are highly appealing
alternatives. These include DNA copy number aberra-
tions and DNA methylation changes in the host cell
genome that result in altered coding and non-coding
gene expression [3].
MicroRNAs (miRNAs) belong to an abundant class of
small non-coding RNAs that post-transcriptionally
regulate gene expression [10]. Altered expression of miR-
NAs has been shown to contribute to human malignan-
cies, including cervical cancer, by influencing expression
of oncogenes and tumor suppressor genes and subsequent
deregulation of important intracellular pathways (reviewed
by [11]). Given their short length of approximately 22
nucleotides, miRNAs are stable biomolecules and are less
prone to degradation than their longer counterparts such
as mRNAs or long non-coding RNAs [10, 12, 13]. It is
therefore not surprising that miRNAs have been suggested
and investigated as biomarkers for cancer diagnostics and
prognostics [14–16].
To identify miRNAs that are relevant to cervical car-
cinogenesis, we previously performed an integrative
screen combining array-based miRNA expression pro-
files with DNA copy number aberrations and DNA
methylation [17, 18]. This resulted in the identification
of five miRNAs for which differential expression was
associated with frequently observed chromosomal gains
of chromosomes 1q and 3q (miR-9-5p, miR-15b-5p,
miR-28-5p) or losses of chromosome 11q (miR-100-5p,
miR-125b-5p), and three miRNAs (miR-149-5p, miR-
203a-3p, miR-375) for which gene silencing was
mediated by DNA methylation of their respective pro-
moter sequences (Table 1). Functional studies for miR-9,
miR-203a, and miR-375 supported the biological
relevance of these miRNA alterations, which were found
to be involved in proliferation and anchorage independ-
ence of HPV-transformed cells [17–19].
In this study, we evaluated the clinical value of the
eight either genetically or epigenetically deregulated
miRNAs to serve as triage markers on cervical scrapes
of hrHPV-positive women in cervical screening. For this
purpose, we verified expression of the discovered 8 miR-
NAs in 58 cervical tissues and archival cervical scrapes
of 225 hrHPV-positive women, built a predictive miRNA
classifier, and evaluated its performance for the detection
of high-grade CIN and cancer using leave-one-out
cross-validation and ROC curve analysis.
Methods
Clinical specimens
Cervical tissue samples consisted of microdissected fresh
frozen specimens, of which the majority has previously
been used for miRNA microarray analysis [17]. In total,
8 normal cervical epithelial samples, 18 high-grade
cervical intraepithelial neoplasia (CIN2–3) lesions, 22
cervical squamous cell carcinomas (SCC), and 11 adeno-
carcinomas (AC) were included. All but one normal
sample were hrHPV-positive. The median age per group
was as follows: normal, 35 years (range 31–47); CIN2–3,
34 years (range 26–54); SCC, 48.5 years (range 25–78);
and AC, 39 years (range 31–64).
Cervical scrapes of 66 hrHPV-positive women without
underlying disease (Pap 1) and 121 women with CIN3
were obtained from a screening population in the Ut-
recht region that had been collected between January
2010 and December 2011. Original 20 ml samples were
Table 1 Candidate miRNAs
miRNA Regulation [17] Potential regulation
mechanism [17, 18]
Class [17]
miR-9-5p Up Chromosomal gain (1q) Late
miR-15b-5p Up Chromosomal gain (3q) Late
miR-28-5p Up Chromosomal gain (3q) Early
continuous
miR-100-5p Down Chromosomal loss (11q) Late
miR-125b-5p Down Chromosomal loss (11q) Late
miR-149-5p Down DNA methylation Early
continuous
miR-203a-3p Down DNA methylation Early
continuous
miR-375 Down DNA methylation Late
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concentrated and stored in 1 ml ThinPrep medium
(Hologic, Vilvoorde, Belgium) at − 80 °C. For most sam-
ples, HPV genotyping was performed using the general
primer GP5+/6 + −mediated PCR-enzyme immunoassay
in combination with the luminex genotyping kit HPV
GP at the time of sample collection [20, 21]. For samples
with sufficient amounts of DNA for which no previous
genotyping results were available, we used the HPV-Risk
Assay (Self-screen BV, Amsterdam, The Netherlands) to
complete our dataset [22]. Women without disease had
a median age of 41 years (range 21–61). The median age
of women with CIN3 was 35 years (range 22–60).
HrHPV-positive scrapes from women with underlying
cervical SCC (n = 29) and AC (n = 9, consisting of 7 AC
and 2 adenosquamous carcinomas) [23, 24] were collected
at the Antoni van Leeuwenhoek Hospital Amsterdam,
The Netherlands, between January 2015 and March 2017.
All cervical cancer samples were tested for hrHPV using
the HPV-Risk Assay. Women with SCC had a median age
of 51 years (range 29–86), and the median age of women
with AC was 45 years (range 27–62).
RNA isolation
Total RNA was isolated using TRIzol reagent (Thermo
Fisher Scientific, Landsmeer, The Netherlands) according to
the manufacturer’s instructions. The Qubit® microRNA
Assay kit was used to quantify small RNA concentrations
on a Qubit® 2.0 Fluorometer (both ThermoFisher Scientific).
Quantitative RT-PCR
Expression of hsa-miR-9-5p, hsa-miR-15b-5p, hsa-
miR-28-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR
-149-5p, hsa-miR-203a-3p, and hsa-miR-375 was
measured using TaqMan microRNA assays (000583,
000390, 000411, 000437, 000449, 002255, 000507,
000564; Thermo Fisher Scientific). For cervical scrapes,
RNU24, RNU43, U6, U75, hsa-miR-423-3p, and hsa-
miR-425-5p were included as potential reference genes
(001001, 001095, 001973, 001219, 002626, 001516;
Thermo Fisher Scientific).
Reverse transcription (RT) of all targets was multi-
plexed and validated in comparison to singleplex RT re-
actions (data not shown). In short, a primer pool was
created by combining the specific RT primers. cDNA
was synthesized from 20 ng small RNA template if avail-
able, for 5 samples the maximum possible amount (<
20 ng) of RNA was used. Each 16 μl reaction contained
6 μl primer pool, 0.3 μl dNTPs (100 mM), 1.5 μl RT
buffer, 0.19 μl RNase inhibitor (20 U/μl), and 3 μl Multi-
Scribe Reverse Trancriptase (TaqMan microRNA
Reverse Transcription kit, Thermo Fisher Scientific).
Quantitative PCR reactions were performed on the ViiA™
7 Real-Time PCR System (Thermo Fisher Scientific) in a
384-well format. Each 10 μl reaction consisted of 5 μl
TaqMan® Universal Master Mix II, 0.5 μl miRNA spe-
cific TaqMan assays (Thermo Fisher Scientific), 3.5 μl
H2O, and 1 μl cDNA. Cycle conditions for cDNA
synthesis and PCR were used according to the manu-
facturer’s protocols.
RNU24 and miR-423-3p were selected for normalization
in cervical tissue samples and scrapes using our previously
published strategy (data not shown) [25]. Data were nor-
malized to the geometric mean Ct of both reference genes
applying the 2−ΔCt method [26]. All samples had a refer-
ence gene geometric mean Ct ≤ 32 and were therefore
considered to be suitable for miRNA expression analysis.
Statistical analysis
Statistical analysis was performed using R version 3.1.2.
For logistic regression, R packages pROC and GRridge
were used. The Spearman correlation coefficient (Rho)
and associated p value was calculated to assess the
agreement between qRT-PCR and previous microarray
results. We performed an omnibus Kruskal-Wallis test
to compare miRNA expression levels between normal,
CIN3, SCC, and AC for each marker. Further, Wilcoxon
rank test was applied with a significance level of 0.05
(two-sided) when the omnibus test showed a significant
result (p < 0.05). p values from the post-hoc test were
corrected with Benjamini-Hochberg correction method.
Individual miRNA models and multi-miRNA classifiers
for the detection of CIN3 were built performing univari-
able and multivariable logistic regression on square root
transformed Ct ratios and evaluated using leave-one-out
cross-validation. As a result, predicted probabilities, i.e.,
values between 0 and 1 representing the risk of an under-
lying CIN3, were calculated for each sample. For the
construction of multi-miRNA classifiers, multivariable
logistic regression analysis was followed by backward
elimination to select relevant markers. Receiver-operated
characteristic (ROC) curve analysis was carried out to
evaluate the performance of the miRNA classifiers in de-
tecting CIN3. For comparison of the obtained AUCs with
a random classifier with AUC = 0.5, DeLong’s test for two
correlated ROC curves was used [27].
Cell culture, transfection, and cell viability assay of cervical
cancer cell lines
Cervical cancer cell lines SiHa and CaSki were authenti-
cated by STR testing using the Powerplex16 System
(Promega, Leiden, The Netherlands) and cultured as
described previously [28]. Cells were transiently trans-
fected with 30 nM miRCURY LNA microRNA Power
inhibitors for miR-15b-5p and negative control A
(4103019, 199006; Exiqon, Vedbaek, Denmark) or
30 nM miRIDIAN microRNA mimics for miR-375 and
negative control #2 (C-300682-05, CN-002000-01; GE
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Dharmacon, Lafayette, CO, USA). Cells were transfected
with Dharmafect 1 (GE Dharmacon) for at least 6 h ac-
cording to the manufacturer’s instructions. After trans-
fection, cells were seeded in triplicate in 96-well plates
(2500 cells/well). Cell viability was measured using the
fluorometric CellTiter-Blue assay (Promega, Madison,
WI, USA) according to the manufacturer’s protocol at
days 0 and 2. The average measurement of day 0 was
subtracted from the measurements at day 2. Each ex-
periment was performed at least two times.
Results
Microarray-based differential miRNA expression in
cervical tissue specimens can be verified by qRT-PCR
To confirm our previously obtained microarray results,
we used qRT-PCR to determine the expression levels of
the eight genetically or epigenetically deregulated miR-
NAs in normal cervical squamous epithelium (n = 8),
high-grade CIN lesions (CIN2–3, n = 18), SCC (n = 22),
and AC (n = 11) tissue specimens, of which 44 had also
been analyzed by microarray [17]. Except for miR-28-5p
and miR-100-5p (Spearman correlation coefficient (Rho)
= 0.521 and Rho = 0.645, respectively), qRT-PCR results
strongly correlated with microarray results as indicated
by Rho > 0.75 (Additional file 1: Figure S1). Because of
the low correlations observed for miR-28-5p and
miR-100-5p, both miRNAs were excluded from further
analysis. Significantly differential expression between
normal and CIN2-3 could be verified for 1 out of 2 up-
regulated miRNAs (miR-9-5p) and for 2 out of 4 down-
regulated miRNAs (miR-149-5p, miR-203a-3p;
Additional file 2: Figure S2 and Additional file 3: Table
S1). Downregulation of miR-375 in CIN2-3 compared to
normal was borderline significant (p = 0.067). All miR-
NAs showed significantly differential expression between
normal and SCC.
Differential miRNA expression is reflected in cervical
scrapes
Next we analyzed whether altered expression of candi-
date miRNAs is also detectable in cervical scrapes.
HrHPV-positive scrapes of women without cervical dis-
ease (normal, n = 66) or with underlying CIN3 (n = 121),
SCC (n = 29), or AC (n = 9) were analyzed by qRT-PCR.
All six miRNAs except for miR-9-5p could be detected
in at least 99% of samples. MiR-9-5p remained un-
detected in about one fourth (23%, 49/212) of samples.
Low expression levels of miR-9-5p were consistent with
microarray and qRT-PCR results obtained in cervical tis-
sue specimens (Fig. 1, Additional file 2: Figure S2).
Because reproducibility is reduced and technical PCR
noise increases when amplifying lowly abundant tran-
scripts [29–31], we did not consider miR-9-5p a suitable
biomarker and excluded it from further analysis. MiRNA
expression results obtained in hrHPV-positive cervical
scrapes were generally comparable to those obtained in
tissue samples (Fig. 1, Additional file 2: Figure S2 and
Additional file 4: Table S2). Expression of miR-15b-5p
was significantly increased in scrapes of women with
CIN3 compared to controls, while miR-125b-5p and
miR-375 were significantly downregulated in scrapes of
women with CIN3. No significant difference between
normal and CIN3 was observed for miR-149-5p and
miR-203a-3p. Similar to observations in tissue samples,
the largest expression change between scrapes of women
with CIN3 and SCC was observed for upregulated
miR-15b-5p. Expression of miR-149-5p and miR-375
was significantly decreased in scrapes of women with
SCC compared to normal and CIN3. Comparison of
normal controls to AC showed a significant increase in
expression of all upregulated miRNAs in scrapes of AC
patients. In accordance with tissue results, miR-125b-5p
and miR-149-5p were significantly downregulated
between normal and AC, and miR-375 did not show a
significant difference between normal scrapes and those
of women with AC.
Predictive miRNA classifier detects large subset of CIN3
lesions
Univariate logistic regression analysis was carried out on
expression results of the five remaining markers
(miR-15b-5p, miR-125b-5p, miR-149-5p, miR-203a-3p
and miR-375) obtained from hrHPV-positive cervical
scrapes of women without cervical disease and women
with underlying CIN3, and validated by leave-one-out
cross-validation. Single miRNAs achieved areas under
the curve (AUC) varying from 0.523 (miR-203a-3p) to
0.605 (miR-125b-5p, Table 2, Fig. 2a).
To determine the most discriminative miRNA marker
panel for CIN3, we performed multivariable logistic re-
gression analysis followed by backward marker selection
and validated results by leave-one-out cross-validation.
This resulted in a 2-miRNA classifier consisting of
miR-15b-5p and miR-375 with an AUC of 0.622 and
optimal sensitivity and specificity of 55 and 70%,
respectively (Table 2, Fig. 2b). Adding additional miR-
NAs to the 2-marker panel did not further improve
performance.
MiRNA classifier detects all cervical carcinomas
To test how our miRNA classifiers performed in the de-
tection of cervical carcinomas, we applied the previously
determined regression models and corresponding cutoffs
to our results obtained on cervical scrapes of women
with underlying SCC or AC. The 2-miRNA classifier
detected all SCC and all AC (Table 3). Overall, the
2-miRNA classifier achieved a CIN3+ detection rate of
65% at 70% specificity.
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HPV16/18 genotyping in conjunction with our miRNA
classifier improves CIN3 detection
To compare the performance of our 2-miRNA classifier
to HPV16/18 genotyping, samples were either classified
as HPV16/18 positive (19 normal, 71 CIN3) or other
hrHPV type positive (46 normal, 37 CIN3), for those
samples for which the genotype was known (n = 173 out
of 187). For this smaller sample set, we built (i) a new
2-miRNA classifier consisting of miR-15b and miR-375
and (ii) a logistic regression model combining the
2-miRNA classifier with HPV16/18 genotyping. Consist-
ent with previous reports, HPV16/18 genotyping
achieved 66% sensitivity and 68% specificity for CIN3
detection (Table 4) [7, 32]. The 2-miRNA classifier
obtained in the smaller sample set had a comparable
performance to the one obtained from the entire set of
samples (Tables 3 and 4). While HPV16/18 genotyping
alone was inferior to the 2-miRNA classifier (p = 5.2
Fig. 1 Differential expression of selected miRNAs in cervical scrapes. qRT-PCR results were normalized to RNU24 and miR-423, and all values were
square root transformed. *p < 0.05, **p < 0.005
Table 2 Comparison of optimal sensitivity and specificity between miRNA panels for the detection of CIN3 based on leave-one-out
cross-validation
Panel AUC Cutoff Sensitivity (%) Specificity (%) p value*
Single markers
miR-15b-5p 0.573 0.629 62.0 56.1 0.098
miR-125b-5p 0.605 0.641 72.7 47.0 0.020
miR-149-5p 0.542 0.597 84.3 28.8 0.356
miR-203a-3p 0.523 0.654 62.0 48.5 0.619
miR-375 0.565 0.671 52.9 62.1 0.145
Two markers
miR-15b-5p/375 0.622 0.682 54.5 69.7 0.006
*p value: comparison between the miRNA classifier and a random classifier with an AUC of 0.5
CIN cervical intraepithelial neoplasia, AUC area under the curve
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e-16, Fig. 3), a classifier combining our two selected
miRNAs with HPV16/18 genotyping had an improved
performance and achieved an AUC of 0.712 (Table 4,
Fig. 3). The 2-miRNA classifier adjusted by HPV16/18
type had a significantly better performance than the
2-miRNA classifier (p = 0.011). Including HPV16/18
genotyping in the classifier increased both sensitivity
and specificity to 63 and 77%, respectively, and all SCC
and AC were detected (data not shown).
Knockdown of miR-15b-5p and ectopic expression of miR-
375 reduces viability in cervical cancer cells
Next, we investigated whether our miRNA markers are
directly involved in cervical carcinogenesis, as is sug-
gested by their genetic (miR-15b-5p) or epigenetic
(miR-375) regulation. Transfection of cervical cancer cell
lines SiHa and CaSki with miR-15b-5p inhibitors led to
a reduction in cell viability, suggesting that miR-15b-5p
acts as an oncomiR (Fig. 4a). Ectopic expression of
miR-375 in SiHa and CaSki cells significantly reduced
cell viability, supporting its role as tumor suppressive
miRNA (Fig. 4b).
Discussion
In this study, we analyzed the triage capacity on
hrHPV-positive cervical scrapes of a panel of miRNAs
that exhibit either genetically or epigenetically mediated
expression changes in cervical precancerous and cancer-
ous tissue specimens and that in part have also been
shown to be functionally involved in cervical carcinogen-
esis [17, 18]. We found that expression patterns detected
in cervical tissue samples were reflected in cervical
scrapes. By logistic regression analysis, a 2-miRNA
classifier was built that at 70% specificity achieved 55%
sensitivity for the detection of CIN3 and 100% sensitivity
for the detection of SCC and AC. Upon inclusion of
HPV16/18 genotyping, the sensitivity and specificity for
CIN3 detection could be increased to 63 and 77%,
respectively. Our data suggest that miRNA expression
analysis offers a promising alternative molecular tool to
triage hrHPV-positive women.
In a systematic review, Sharma et al. identified a total
of 246 miRNAs that become deregulated in cervical
cancer, with miR-21, miR-143, miR-145, miR-203,
miR-214, and miR-218 being the most frequently
described [33]. Most published studies identified deregu-
lated miRNAs in cervical tissue samples by microarray
analysis [17, 34, 35]. Studies focusing on the diagnostic
or prognostic use of miRNAs detected by qRT-PCR in
cervical biopsies are numerous, as are studies investigat-
ing the functional contribution of individual miRNAs to
cervical cancer development. Data on the clinical applic-
ability of miRNA expression analysis in cervical scrapes
for cervical screening purposes, however, is limited. To
a b
Fig. 2 ROC curve analysis of miRNA classifiers for the detection of CIN3. Results obtained from 66 hrHPV-positive scrapes from women without
underlying disease and 121 scrapes from women with CIN3 were used to build (a) individual miRNA classifiers and (b) a 2-miRNA classifier.
Classifiers were validated by leave-one-out cross-validation
Table 3 Sensitivity of miRNA panels for the detection of SCC
and AC
Panel Sensitivity %









SCC squamous cell carcinoma, AC adenocarcinoma
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the best of our knowledge, only Tian et al. published on
the analysis of a panel of candidate miRNA markers in
HPV-positive scrapes of a gynecology outpatient clinic
population to date [36]. Candidate miRNAs analyzed by
Tian et al. have previously been shown to become differ-
entially expressed during disease progression. A combin-
ation of miR-375 and miR-424 resulted in an AUC value
of 0.853 for the detection of CIN3+, showing the
promise of biologically relevant miRNAs as disease
markers. Importantly, our study as well as the study by
Tian et al. shows that the use of more than one miRNA
improves detection of cervical disease. Although
miR-15b-5p alone detected all carcinomas, combining
miR-15b-5p with miR-375 proved beneficial for the
detection of CIN3 without a loss of sensitivity for SCC
and AC. The fact that the individual miRNA performing
best in the detection of CIN3 (miR-125b-5p) was not in-
cluded in the 2-miRNA classifier further demonstrates
that analysis of multiple complementary miRNAs can
improve the detection of cervical disease. Importantly,
we here show that combining miRNA profiling with
HPV16/18 genotyping can further improve the detection
of cervical precancer. This is especially attractive, as
HPV16/18 genotyping is frequently included in clinically
validated HPV tests [20, 37] and HPV16/18 genotyping
and miRNA expression analysis can be performed on
the same cervical scrape.
In line with Tian et al., our study shows that downreg-
ulated miRNAs can be suitable biomarkers, although the
selection of downregulated markers may seem counter-
intuitive at first. It is important to note that the relative
decrease in expression observed with cervical disease
progression does not give an indication of the absolute
abundance of a miRNA. Differences in performance be-
tween the study of Tian et al. and ours are most likely
due to differences between study populations. While our
cohort of cervical scrapes was obtained from a screening
population, Tian et al. analyzed scrapes from a
clinic-based referral population, which potentially con-
tains more advanced CIN lesions. Altered expression of
our candidate miRNAs is caused by either genetic or
epigenetic changes which have previously been shown to
be associated with cervical cancer and so-called
advanced CIN3 lesions [3]. Their association with pro-
gression risk to cancer could explain why our miRNA
classifiers detect only a subset of CIN3 lesions. Our
2-miRNA classifier detected all cervical cancers and 55%
of CIN3 at 70% specificity, a generally accepted specifi-
city for triage markers [38]. At present, adopted triage
options for HPV-positive women include reflex cytology,
HPV16/18 genotyping, repeat HPV testing, and/or re-
peat cytology. While triage by the current miRNA panel
does not yet meet the criteria for acceptability of a triage
strategy [39], we here show that triage by miRNA ex-
pression analysis is feasible and offers a promising alter-
native. MiRNA analysis is objective, highly reproducible,
Table 4 Optimal sensitivity and specificity for the detection of CIN3 for hrHPV type (HPV16/18, others) and the miRNA classifier in
conjunction with hrHPV type based on a smaller sample set with known hrHPV type infection and leave-one-out cross-validation
Panel AUC Cutoff Sensitivity % Specificity % p value*
Single marker
HPV type 0.445 n.a. 65.7 67.7 0.266
Multiple markers
miR-15b-5p/375 0.622 0.656 55.6 69.2 0.008
miR-15b-5p/375/HPV 0.712 0.666 63.0 76.9 5.8 e-07
*p value: comparison between the miRNA classifier and a random classifier with an AUC of 0.5
CIN cervical intraepithelial neoplasia, AUC area under the curve, n.a not applicable
Fig. 3 ROC curve analysis of HPV16/18 genotyping and the 2-miRNA
classifier for the detection of CIN3. Results obtained from scrapes with
known HPV16/18 genotyping results (65 normal, 108 CIN3) were used
to build classifiers for HPV16/18 genotyping (HPV), a new 2-miRNA
classifier (miR-15b/375) and the 2-miRNA classifier combined with
HPV16/18 genotyping (miR-15b/375/HPV). Classifiers were validated
by leave-one-out cross-validation. The model miR-15b/375/HPV is
significantly better than the 2-miRNA classifier (p = 0.011)
Babion et al. Clinical Epigenetics  (2018) 10:76 Page 7 of 10
and can be performed in a high-throughput manner. We
do acknowledge that further panel optimization is
required and expect that analysis of additional miRNAs
will result in a miRNA classifier with improved perform-
ance. How an optimized miRNA panel performs in
comparison to or as adjunct to cytology, HPV16/18
genotyping, DNA methylation markers, and/or other
cellular markers such as p16INK4A/Ki-67 will be subject
of future studies.
Overexpression of miR-15b-5p has previously been as-
sociated with HPV-induced malignancies including
cervical cancer, tonsillar tumors, and anal carcinomas
[40, 41]. Moreover, miR-15b-5p was shown to promote
cell viability, migration, and invasion in non-small cell
lung cancer by targeting metastasis suppressor TIMP2
[42]. In line with this, we observed reduced cervical
cancer cell viability upon knockdown of miR-15b-5p
suggestive of an oncogenic role for this miRNA. Expres-
sion of miR-375 in cervical cancer, on the other hand, is
downregulated by increased DNA methylation as well as
by a frequently occurring focal loss of chromosome
2q35 [18, 19, 43, 44]. In line with literature, we found
that ectopic expression of miR-375 in hrHPV-positive
cervical cancer cell lines reduces cell viability [19, 45].
Jung et al. previously showed that miR-375 restored
major tumor suppressors p53, p21, and RB levels by de-
regulation of HPV16 and HPV18 viral transcripts and
directly targeting E6AP [45].
One limitation of this study is that we did not include
HPV-positive scrapes of women diagnosed with CIN1
and CIN2. Further validation of our 2-miRNA classifier
is needed in an independent population-based screening
cohort consisting of consecutive hrHPV-positive cervical
scrapes including CIN1 and CIN2 lesions. In addition,
the samples used in our study had been stored at room
temperature for at least 1 year and at − 80 °C for another
3 to 4 years, and clinical material was limited. We
showed that using as little as 20 ng of small RNA still
enables the early detection of cervical cancer, but we
cannot exclude that higher amounts of RNA, as also
used by Tian et al., may give a better discrimination be-
tween normal and CIN3. On the other hand, our data
also demonstrate that miRNAs are very stable molecules.
This is of particular importance in screening settings
where cervical scrape material is send to central diag-
nostic laboratories for molecular testing. While we
a
b
Fig. 4 Functional effect of our selected marker miRNAs in cervical cancer cell lines. Cell viability of SiHa and CaSki cells upon (a) knockdown of
miR-15b-5p and (b) ectopic expression of miR-375. Results are representative of two independent experiments
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analyzed a selected panel of eight miRNAs which were
shown to become genetically or epigenetically deregu-
lated during cervical carcinogenesis in cervical tissue
samples, candidate miRNAs should ideally be selected
directly from whole miRNome data obtained from cer-
vical scrapes [46]. Future studies will therefore aim to
identify an optimal panel of miRNAs for the detection of
CIN3 and cancer.
Conclusions
In conclusion, present data show that analysis of differ-
entially expressed miRNAs may provide an alternative
molecular triage strategy in hrHPV-based cervical
screening. Our data indicate that miRNAs that are
genetically or epigenetically deregulated during and dir-
ectly involved in disease progression are promising
biomarkers for the detection of cervical cancer and a
subset of CIN3 lesions. CIN3 detection was further im-
proved by inclusion of HPV16/18 genotyping. Further
optimization of the marker panel and validation in an
independent cohort of hrHPV-positive cervical scrapes
will reveal whether triage of hrHPV-positive women by
miRNA expression analysis offers an objective and
economical alternative to cytology.
Additional files
Additional file 1: Figure S1. Correlation between microarray and qRT-
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